Gruss Capital Management’s Filana Therapeutics FLNA Stock Holding History

Gruss Capital Management’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-89,286	Closed	-$2.44M	–	96
2014 Q3	$2.44M	Buy	89,286 +3,572	+4%	+$109K	0.11%	51
2014 Q2	$3.45M	Sell	85,714 -19,973	-19%	-$739K	0.17%	51
2014 Q1	$4.07M	Sell	105,687 -7,143	-6%	-$252K	0.25%	41
2013 Q4	$3.84M	Hold	112,830	–	–	0.29%	36
2013 Q3	$2.15M	Buy	112,830 +7,143	+7%	+$125K	0.21%	44
2013 Q2	$1.64M	Buy	+105,687	New	+$2.23M	0.18%	44

Other funds holding FLNA

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Gruss Capital Management's FLNA Position: Q4 2014 in Review

Gruss Capital Management sold out of Filana Therapeutics (FLNA) in Q4 2014, closing a stake of 89,286 shares — an estimated $2.44M sold.

Gruss Capital Management first reported a position in FLNA in Q2 2013 and held it in 6 quarters. The position peaked at $4.07M in Q1 2014. 66 funds tracked by Wall St. Rank hold FLNA as of Q4 2014.

Gruss Capital Management reported no remaining Filana Therapeutics position as of Q4 2014 after selling out during the quarter.
Gruss Capital Management sold 89,286 Filana Therapeutics shares in Q4 2014, an estimated $2.44M.
Gruss Capital Management first reported a position in Filana Therapeutics in Q2 2013 and held it in 6 quarters.
Gruss Capital Management's Filana Therapeutics position peaked at $4.07M in Q1 2014.
66 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2014.

Based on Gruss Capital Management's 13F filing for Q4 2014, filed 13 Feb 2015.